Navigation Links
Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
Date:2/11/2011

SAN DIEGO, Feb. 11, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced the closing of a $20 million Series B Preferred Stock private placement financing.  This financing was led by new investor, AgeChem Venture Fund of Montreal, Canada, and included participation by existing investors; Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners, and Roche Venture Fund.  Conatus will use the proceeds to advance the clinical development of CTS-1027, a novel clinical-stage drug candidate the Company has licensed from F. Hoffman-La Roche, Ltd. and is the subject of multiple Phase 2 clinical trials in hepatitis C (HCV)-infected patients.  

As part of the financing, Louis Lacasse from AgeChem will join the Conatus Board of Directors. "We are very excited about joining such an elite group of investors to support the development of CTS-1027 which we believe could be a blockbuster drug for the treatment of HCV infections," said Louis Lacasse.

Continuing Board Directors are Paul Klingenstein from Aberdare Ventures, Shahzad Malik, M.D., from Advent Venture Partners, William Gerber, M.D., from Bay City Capital, and Marc Perret from Gilde Healthcare, and independent directors, David Hale and Hal Van Wart, Ph.D. Steven J. Mento, Ph.D., Co-founder, President and CEO of Conatus, will continue as Chairman of the Board.

Concurrent with the first closing of the Series B financing, Conatus also converted promissory bridge notes into Series B preferred stock.

The Series B financing will remain open for an additional period as other potential investors conclude their diligence.

"This financing enables Conatus to expand the clinical development of CTS-1027 as a cell-based antiviral for the treatment of HCV infections. We believe that CTS-1027 represents a novel approach to treating HCV disease and look forward to developing this drug candidate in the HCV-null responder population in combinatio
'/>"/>

SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
2. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
3. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
4. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
5. Conatus Pharmaceuticals Acquires Pfizers Idun Subsidiary
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), ... of new cancer therapies, today announced its financial results ... provided an overview of recent Company highlights and expected ... host a business update conference call and live webcast ...
(Date:9/3/2015)... 3, 2015 Report Details ... that Market, its R&D and Sales Potentials ... of cancer-treating medicines? Visiongain,s new report gives you revenue predictions ... you discover financial data, R&D trends, opportunities, interviews and revenue ... analysis you see forecasted sales to 2025 at overall world ...
(Date:9/3/2015)... About cardiovascular implants ... or blockage of blood vessels. Cardiac disease is ... cholesterol, and high blood pressure. Coronary artery disease, ... failure are some of the major cardiac diseases. ... coronary arteries, is one of the most common ...
Breaking Medicine Technology:DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 3DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 4DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 5DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 6DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 7DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 8World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7Global Cardiovascular Implants Market 2015-2019 2
(Date:9/5/2015)... ... September 05, 2015 , ... Watching a cyber nightmare come to life in the privacy of ... do nothing more than sit back helplessly as a hacker took control over their digital ... while it may have made the whole situation that much more jarring to the senses ...
(Date:9/4/2015)... ... 2015 , ... According to an article published August 4th by ... data showing that it is safe for pregnant women to undergo local anesthesia needed ... local anesthesia with a group that hadn’t, researchers were able to determine that “local ...
(Date:9/4/2015)... ... 04, 2015 , ... The Providence Fertility Center will host a Fertility Cocktail ... egg freezing. , Date and Time: October 8, 2015 at Waterman Grille restaurant and ... informative event will discuss the basics of female fertility and egg freezing, and offer ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... benefit Core Compassion Project. Core Compassion Project is a non-profit organization dedicated ... reduce the side effects of cancer treatments and recover their mobility, strength, and ...
(Date:9/4/2015)... ... September 04, 2015 , ... Mike Day, a former Navy ... compete in the Ironman World Championships in Kona on October 10th. , Mike is ... Brain Injury (TBI) through combat and the cutting-edge treatments that restore their quality of ...
Breaking Medicine News(10 mins):Health News:IT Security Beware: A Cyber Security Nightmare at Work Can Start at Home 2Health News:IT Security Beware: A Cyber Security Nightmare at Work Can Start at Home 3Health News:IT Security Beware: A Cyber Security Nightmare at Work Can Start at Home 4Health News:Recent Study on Dental Care During Pregnancy Demonstrates How Preventative Dental Care Really is for Everyone, Says Medical Center Dental Care 2Health News:The Providence Fertility Center to Host Fertility Cocktail Hour on October 8, 2015 at Waterman Grille for Women Who Wish to Learn About Their Fertility and Egg Freezing 2Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2
... women who take combined estrogen/progestin hormone-replacement therapy for ... risk of developing various forms of lobular breast ... Fred Hutchinson Cancer Research Center., Previous research indicated ... use was necessary to increase overall breast-cancer risk, ...
... Jan. 15, 2008 Hormonal components in over-the-counter ... cancer and decrease the effectiveness of anti-cancer drugs, ... , The findings, which appear in todays issue ... patients should inform their doctors about any herbal ...
... feature promotes a more informed health care experience, ... regional studies,indicate that informed patients make better health ... launching a member feedback feature in,Spring 2008 that ... share,information with each other about their provider experiences ...
... Ltd., (Amex: CPD ) announced today that ... final approval for the Company,s,Abbreviated New Drug Application ... and 5/500 mg,(Glipizide/Metformin HCl)., Glipizide/Metformin HCl is ... and exercise, to improve glycemic control in patients ...
... Jan. 14 Three Rivers,Pharmaceuticals, LLC finalized acquisition ... International (NYSE: VRX ). Valeant is,receiving $91 ... "Adding Infergen to our growing portfolio is very ... and chief executive,officer. "This purchase is only a ...
... in Medical Products, Specialty Coatings, ... Transportation and Print Solutions, DETROIT, Jan. ... quarter of 2007 the firm added five companies to its,portfolio, ... completed 14,acquisition and divestiture transactions valued at over $225 million. ...
Cached Medicine News:Health News:Combined HRT increases risk of lobular breast cancer fourfold after just 3 years of use 2Health News:Hormonal dietary supplements might promote prostate cancer progression 2Health News:Hormonal dietary supplements might promote prostate cancer progression 3Health News:Regence Enables Members to Share Feedback With Each Other When Researching Health Care Provider Options 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R) 2Health News:Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals 2Health News:Huron Capital Caps Strong Year With Five Acquisitions In 4Q07 2Health News:Huron Capital Caps Strong Year With Five Acquisitions In 4Q07 3
PremierEdge™ MVR Knives. Angled....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
As pupil size continues to play a significant role in the outcomes of refractive surgery, the pre-operative use of the Colvard Pupillometer continues to be the standard of care for obtaining accurate...
Medicine Products: